MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The severity and distribution of tau pathology distinguish corticobasal degeneration and progressive supranuclear palsy

S. Koga, N. Ghayal, S. Roemer, D. Dickson (Jacksonville, FL, USA)

Meeting: MDS Virtual Congress 2020

Abstract Number: 1113

Keywords: Corticobasal degeneration (CBD), Progressive supranuclear palsy(PSP), Tauopathies

Category: Parkinsonism, Atypical: PSP, CBD

Objective: To elucidate whether the severity and distribution of tau pathology reflect the clinical presentations in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD).

Background: PSP and CBD are progressive neurodegenerative diseases characterized by the accumulation of tau proteins in both neuronal and glial cells in the gray and white matter of the neocortex, basal ganglia, diencephalon, and brainstem. Despite the similarity of neuropathology, PSP and CBD are considered distinct tauopathies. Tufted astrocytes are pathologic hallmarks of PSP, while astrocytic plaques are exclusively seen in CBD. Clinical presentations of PSP and CBD are heterogeneous, exemplified by Richardson syndrome (RS), corticobasal syndrome (CBS), frontotemporal dementia (FTD). Thus, it is challenging to predict underlying pathology based on clinical presentations.

Method: We reviewed clinical presentations and underlying pathology of 983 autopsy-confirmed PSP and 178 CBD brains. The severity of tau pathology, including neurofibrillary tangles, pretangles, coiled bodies, tufted astrocytes in PSP or astrocytic plaques in CBD, and threads was graded semi-quantitatively on a four-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe) in 8 brain regions: inferior temporal gyrus, motor cortex, caudate, globus pallidus, subthalamic nucleus, red nucleus, substantia nigra, and midbrain tectum. Concurrent pathologies, including Alzheimer’s disease and argyrophilic grain disease, were also assessed. Cluster analysis was performed based on the topographical distribution and severity of tau pathology. Demographics, clinical presentation, co-pathologies, were compared among the clusters.

Results: The cluster analysis divided all cases into three clusters. Cluster 1 consists of 170 CBD and 2 PSP cases; Cluster 2 consists of 3 CBD and 241 PSP cases; and Cluster 3 consists of 5 CBD and 740 PSP cases. Clinical presentations of each clusters were as follows: RS (45%), CBS (32%), and FTD (8%) in Cluster 1; RS (82%), CBS (6%), and FTD (1%) in Clusters 2; and RS (84%), CBS (6%), and FTD (1%).

Conclusion: The distribution and severity of 8 brain regions were distinct between PSP and CBD. In contrast, clinical presentations were heterogeneous within the cluster, indicating that the severity and distribution of tau pathology were insufficient to predict clinical presentations.

To cite this abstract in AMA style:

S. Koga, N. Ghayal, S. Roemer, D. Dickson. The severity and distribution of tau pathology distinguish corticobasal degeneration and progressive supranuclear palsy [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/the-severity-and-distribution-of-tau-pathology-distinguish-corticobasal-degeneration-and-progressive-supranuclear-palsy/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-severity-and-distribution-of-tau-pathology-distinguish-corticobasal-degeneration-and-progressive-supranuclear-palsy/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley